the aid library

LIST OPTIONS

Filter

338

JOIN European First Aid Guidelines
recommended

Johanniter International (2022) C2

In the event of an accident or medical emergency, First Aid saves lives. Keeping the patient alive and safe until the arrival of expert professional help is a vital part of the chain of care which leads to recovery. The principle of First Aid must be simple skills, clearly taught and capable of bein... more

Download (129)

View PDF (189)

Criterios de diagnóstico y tratamiento de la tuberculosis infantil

Gonzales N., et al. (2022) CC

El agente etiológico de la tuberculosis es el Mycobacterium tuberculosis o bacilo de Koch. Se trata de un bacilo aerobio estricto, ácido-alcohol resistente, sin movilidad, de crecimiento lento y que se inactiva con rayos ultravioleta y temperaturas mayores de 60°C.

Download (104)

View PDF (124)

COVID-19: Implications for People with Chagas Disease

Zaidel, E.J.; et al. (2020) CC

Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.

Download (165)

View PDF (168)

Guía de medicamentos esenciales para primer nivel de atención – Edición 2019

Ministerio der Salud Argentina (2019) C2

Guía de medicamentos esenciales para primer nivel de atención – Edición 2019

Download (203)

View PDF (270)

Hepatitis Virales - Guía para el diagnóstico y tratamiento de la infección por el virus de las hepatitis B y C

Coordinación Nacional de Hepatitis Virales Ministerio de Salud Argentina (2021) C2

Los objetivos de las guías son brindar directrices para optimizar el cuidado de la mayoría de los pacientes afectados por los VHB y VHC. Sin embargo, no reemplazan el criterio médico en la valoración y abordaje del paciente individual. En situaciones especiales, el mejor enfoque en el diagnóst... more

Enfermedad de chagas-memorias

Ministerio de Salud y Protección Social, Colombia (2012) C2

La enfermedad de Chagas (ECha), resultado de la infección por el Trypanosoma cruzi, afecta varias poblaciones de las zonas rurales de Suramérica y América Central. En los últimos años la enfermedad ha cobrado importancia epidemiológica no sólo porque se ha incrementado la detección de caso... more

Lista Nacional de Medicamentos Esenciales - Bolivia

Ministerio de Salud Bolivia (2022) C2

Lista Nacional de Medicamentos Esenciales

Responding to outbreaks of antimicrobial-resistant pathogens in health-care facilities: guidance for the Western Pacific region

World Health Organization WHO (2022) C_WHO

Responding to Outbreaks of Antimicrobial-resistant Pathogens in Health-care Facilities: Guidance for the Western Pacific Region is developed following requests from Member States in the Western Pacific Region for additional information and support in managing AMR outbreaks. It aims to provide: a ste... more

Download (158)

View PDF (198)

Manuel de l’Utilisation Optimale du Sang

Optimal Blood Use Project (2010) CC

La sécurité du traitement hospitalier et la réalité des soins sont des préoccupations majeures dans les systèmes de santé. La transfusion sanguine a fait l’objet de procédures juridiques et d’études au Canada, en Angleterre, en France, en Irlande et dans d’autres pays. Il conviendr... more

Tracking official development assistance for reproductive health in conflict-affected countries: 2002—2011

Patel P.; Dahab M.; Tanabe M. et al. BJOG An International Journal of Obstetics and Gynaecology (2016) CC

To provide information on trends on official development assistance (ODA) disbursement patterns for reproductive health activities in 18 conflict-affected countries

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

External Link

Primary and Secondary Prevention of Ischemic Stroke

Paciaroni, M.; Bogousslavsky, J. European Neurology (2010) CC

Prevention of stroke and transient ischemic attack includes both conventional approaches to vascular risk factor management (blood pressure lowering, cholesterol reduction with statins, smoking cessation and antiplatelet therapy) and more specific interventions, such as carotid revascularization or... more

External Link

World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update

Freedman, B.; Hindricks, G.; Banerjee, A. Global Heart (2021) CC

The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death... more

External Link

Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward

Minja, N.W.; Nakagaayi, D.; Aliku, T. et al. Frontiers in Cardiovascular Medicine (2022) CC

In 2015, the United Nations set important targets to reduce premature cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately bears the brunt of CVD burden and has one of the highest risks of dying from non-communicable diseases (NCDs) worldwide. There is currently an epide...miological transition on the continent, where NCDs is projected to outpace communicable diseases within the current decade. Unchecked increases in CVD risk factors have contributed to the growing burden of three major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age standardized disability-adjusted life years (DALYs) due to hypertensive heart disease (HHD) were recorded in Africa. The contributory causes of heart failure are changing—whilst HHD and cardiomyopathies still dominate, ischemic heart disease is rapidly becoming a significant contributor, whilst rheumatic heart disease (RHD) has shown a gradual decline. In a continent where health systems are traditionally geared toward addressing communicable diseases, several gaps exist to adequately meet the growing demand imposed by CVDs. Among these, high-quality research to inform interventions, underfunded health systems with high out-of-pocket costs, limited accessibility and affordability of essential medicines, CVD preventive services, and skill shortages. Overall, the African continent progress toward a third reduction in premature mortality come 2030 is lagging behind. More can be done in the arena of effective policy implementation for risk factor reduction and CVD prevention, increasing health financing and focusing on strengthening primary health care services for prevention and treatment of CVDs, whilst ensuring availability and affordability of quality medicines. Further, investing in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on interventions. This review summarizes the current CVD burden, important gaps in cardiovascular medicine in Africa, and further highlights priority areas where efforts could be intensified in the next decade with potential to improve the current rate of progress toward achieving a 33% reduction in CVD mortality. more

Download (49)

View PDF (54)

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Bazargani, Y.T.; Ugurlu, M.; Leufkens, H.G.M. et al. BMC Cardiovascular Disorders (2018) CC

The incidence and mortality of cardiovascular diseases (CVDs) in low and middle income countries (LMICs) have been increasing, while access to CVDs medicines is suboptimal. We assessed selection of essential medicines for the prevention and treatment of CVDs on national essential medicines lists (NE... more

National Guidelines for the Management of Cardiovascular Diseases

Ministry of Health Ghana Republic of Ghana (2019) CC

Cardiovascular diseases (CVDs) are a growing public health problem in Ghana and other African countries. Strokes and other CVDs have become a leading cause of death due to increasing risk factors such as hypertension. According to the Global Burden of Disease study (GBD), ischaemic heart disease was... more

Management of Type 2 Diabetes Mellitus

Richardson, C.R.; Borgeson, J. R.; Harrison, V.; et al. National Library of Medicine (2021) CC2

The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio... more

JOIN European First Aid Guidelines recommended

JOIN European First Aid Guidelines
recommended